In Canada, a disease is generally considered rare when it affects fewer than 1 in 2,000 people. That sounds like a small number, and for any single condition it is. But there are roughly 7,000 distinct rare diseases, and together they affect about 1 in 12 Canadians.
Rare individually, common collectively
This is the central paradox of rare disease. Each condition has a small patient population, so each one gets little research attention, few specialists and often no approved treatment. Yet anyone who has a family member, a neighbour or a colleague living with one knows how many people are affected in total.
Most are genetic, many start in childhood
A large share of rare diseases have a genetic cause, and many appear in infancy or childhood. Others are rare cancers, autoimmune conditions or infectious diseases. This variety is part of why the field is hard: there is no single pathway, biomarker or drug class that covers it.
Why the definition matters
Whether a condition is classified as rare affects whether it qualifies for orphan drug incentives, special review pathways and dedicated funding. For patients, it can decide whether a therapy is ever developed at all.
Where data helps
Because patient numbers are small, no single hospital or trial sees enough cases. Combining anonymized genomic, phenotypic and clinical data across organizations is one of the few ways to see patterns that would otherwise stay hidden. That is the problem RareGeno was built to work on.
Curious how this works in practice? Learn about the RareGeno approach or try our free research tool.